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Abstract
Crimean-Congo hemorrhagic fever (CCHF) is a zoonosis caused by a Nairovirus of the family Bunyaviridae. Infection is
transmitted to humans mostly by Hyalomma ticks and also by direct contact with the blood or tissues of infected humans or
viremic livestock. Clinical features usually include a rapid progression characterized by hemorrhage, myalgia and fever, with
a lethality rate up to 30%. CCHF is one of the most widely distributed viral hemorrhagic fevers and has been reported in
Africa, the Middle East and Asia, as well as parts of Europe. There is no approved vaccine or specific treatment against CCHF
virus (CCHFV) infections. In this context, an accurate diagnosis as well as a reliable surveillance of CCHFV infections is
essential. Diagnostic techniques include virus culture, serology and molecular methods, which are now increasingly used.
The European Network for the Diagnostics of ‘‘Imported’’ Viral Diseases organized the first international external quality
assessment of CCHVF molecular diagnostics in 2011 to assess the efficiency and accurateness of CCHFV molecular methods
applied by expert laboratories. A proficiency test panel of 15 samples was distributed to the participants including 10
different CCHFV preparations generated from infected cell cultures, a preparation of plasmid cloned with the nucleoprotein
of CCHFV, two CCHFV RNA preparations and two negative controls. Forty-four laboratories worldwide participated in the
EQA study and 53 data sets were received. Twenty data sets (38%) met all criteria with optimal performance, 10 (19%) with
acceptable performance, while 23 (43%) reported results showing a need for improvement. Differences in performance
depended on the method used, the type of strain tested, the concentration of the sample tested and the laboratory
performing the test. These results indicate that there is still a need for improving testing conditions and standardizing
protocols for the molecular detection of Crimean-Congo hemorrhagic fever virus.
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Introduction
Crimean-Congo hemorrhagic fever (CCHF) is an acute and
highly contagious viral disease with high case fatality rate. It is
caused by CCHF virus (CCHFV), a segmented, negative-stranded
RNA virus belonging to the genus Nairovirus in the Bunyaviridae
family. Transmission to humans occurs mainly by tick bites (mainly
of the genus Hyalomma), but also by exposure to body fluidsor tissues
of viremic patients or animals. Livestock such as cattle, sheep, goats,
hares and pigs can host CCHFV without showing any symptoms
[1]. In humans, CCHF typically presents with sudden onset of high
fever, severe myalgia, malaise and gastrointestinal symptoms.
Frequent extensive hemorrhages may occur at later stages of the
disease leading to a high fatality rate (up to 50%) [2,3].
Following dengue viruses, CCHFV is one of the most wide-
spread medically important arboviruses. The geographic range of
CCHFV includes Africa, Asia, and Eastern Europe. In Europe,
CCHF is endemic in Bulgaria since the 1950s and during the last
decadeCCHF outbreaks and cases have increased in several Balkan
countries, Ukraine, Turkey and south-western regions of the
Russian Federation with significantly high fatality rates [4–14]. A
CCHF case was notified for the first time in Greece in June 2008
[15]. Several imported cases have also been reported lately [16,17].
Changes in climatic conditions could expand the range of its tick
vectors, and increase the incidence of disease.
Several factors have made CCHFV become an important public
health issue including its wide and extending geographical
distribution, its potential to cause outbreaks and highly fatal disease
in humans, the lack of vaccine, limited treatment options as well as
fears about its use as a biological agent by terrorists or criminals.
Due to its potential to cause community and nosocomial out-
breaks, a quick and accurate diagnosis of CCHF is important for
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diagnosis of patients decreases treatment efficacy and increases the
risk of fatal outcome.
Diagnostic assays for CCHFV include virus isolation, enzyme-
linked immunosorbent assays and reverse transcription–PCR (RT-
PCR) [1,3]. Virus isolation is very constraining as it must be
performed in high biocontainment laboratories of biosecurity level
4 (BSL4). Molecular methods for the detection of the viral genome
offer a rapid, sensitive, and highly specific alternative for early
diagnosis during the viremic phase of infection or in post-mortem
tissues. However, because of the remarkable genetic variability
among CCHFV strains, most current RT-PCRs either fail to
detect specific strains or lack sensitivity [18]. A further improve-
ment has been the development of real-time RT-PCRs, which
have higher specificity and sensitivity, higher time-effectiveness
and lower risk of contamination than conventional RT-PCR [19–
21].
The performance of the different techniques applied for mole-
cular diagnosis of CCHFV may vary between laboratories and
external quality assessment (EQA) studies to assess the quality of
CCHF molecular diagnostics have not been performed until now.
For this reason, the European Network for Diagnostics of
‘Imported’ Viral Diseases (ENIVD) (http://www.enivd.org) orga-
nized the first EQA study for molecular diagnosis of CCHFV in
2011 with 44 laboratories participating from 29 different countries
worldwide. Such studies allow the participating laboratories to
monitor the quality of current diagnosis, highlight possible weak
points in particular techniques and evaluate their capacity for
surveillance activities. Using the results of this study, the ENIVD
can also provide support and advice to all participants and
laboratories performing CCHFV molecular diagnosis.
Materials and Methods
Call for participation
A total of 47 laboratories involved in diagnostics of CCHF
infections were invited to participate in this study. Invitees are
members of the ENIVD or national/regional reference laborato-
ries for CCHF or vector-borne diseases. The study was announced
as an EQA for the molecular diagnosis of CCHFV infections
involving the publication of results in a comparative and
anonymous manner.
This EQA was coordinated by the ENIVD following similar
procedures as during previous studies performed by the network
[22–24].
Specimen preparation
A proficiency test panel of 15 samples was prepared which
included inactivated and stable CCHFV preparations generated
from Vero E6 cell culture supernatants of 4 different CCHFV
genotypes: Europe 1 (strain Hoti, isolated in Kosovo), Asia 1
(strain Afg09-2990, isolated from a human CCHFV infection
acquired in Afghanistan), Africa 3 (strain ArD 39554, isolated in
Mauritania) and Europe 2 (strain AP-92, isolated in Greece). Viral
cell supernatants were inactivated by heating for 1 h at 60uC and
gamma irradiation (25 kilogray) to assure their non-infectivity [25–
29]. The panel also included a preparation of a plasmid (pGEM-
4Z, Promega) cloned with the nucleoprotein (NP) sequence of
strain CCHFV IbAr 10200 and two RNA preparations extracted
from cultures of CCHFV isolates from Iran and Greece. All
samples were diluted with fresh frozen plasma previously con-
firmed as negative for CCHFV. Aliquots of 100 ml were number-
coded, freeze dried for 24 h (Christ, AlphaI-5, Hanau, Germany)
and stored at 4uC until dispatch.
The EQA panel was composed of:
N 5 serial 10-fold dilutions of CCHFV positive sera, genotype
Europe 1
N 3 serial 10-fold dilutions of CCHFV positive sera, genotype
Asia 1
N 1 positive sample of CCHFV positive sera, genotype Europe 2
N 1 positive sample of CCHFV positive sera, genotype Africa 3
N 1 sample of CCHFV NP cloned in pGEM-4Z
N 2 samples containing extracted RNA from 2 different CCHFV
isolates
N 2 negative controls
Validation and dispatch of the panel sets
To validate the molecular panel, 3 different sets of EQA
samples were tested by expert laboratories before distribution
by the Robert Koch Institute (RKI), Berlin, Germany. After
reconstitution with 100 ml of water, the samples were extracted
using the QIAamp viral RNA minikit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. As above mentioned,
we estimated the CCHFV genome copies present in these samples
by real time RT-PCR.
The EQA panels were distributed to participants with full
instructions. Samples were shipped by normal post at ambient
temperature to the participating laboratories. We requested par-
ticipant laboratories to resuspend the samples in 100 ml of water
and to analyze the material as serum samples for detection of
CCHFV RNA. They were asked to report their results and any
problems encountered as well as information on the chosen
protocol using a common formulary included in the documenta-
tion.
A time-stability control of the EQA samples was additionally
performed by a reference laboratory by testing the samples at two
different time points with a 3 months interval.
Author Summary
Crimean-Congo hemorrhagic fever (CCHF) is a widely
distributed viral hemorrhagic fever as the disease occurs in
much of Africa, the Middle East and Asia, Balkans and
Russia. CCHF is a zoonotic viral disease mainly transmitted
by ticks, although animal-to-human and human-to-human
transmission also occurs. CCHF is asymptomatic in animals
but presents a serious threat to humans causing nonspe-
cific flu-like symptoms that may progress to a serious
hemorrhagic syndrome with a fatality rate up to 50%.
There is no approved vaccine or antiviral treatment against
CCHF infections and antiviral treatment relies on early
confirmation of the disease. In this context, accurate
diagnosis and reliable surveillance of CCHF is essential.
Diagnostic techniques for CCHF virus (CCHFV) rely more
and more on molecular methods, which are rapid, simple
and sensitive when correctly standardized. In this study,
we present the results of the first international external
quality assurance (EQA) for molecular diagnosis of CCHFV.
The objective of this EQA is to collect information on the
efficiency and accurateness of CCHFV molecular methods
applied by expert laboratories. Participants included 44
expert laboratories from 29 different countries worldwide.
The study shows uneven performances indicating that
there is still a need for improving testing conditions and
standardizing protocols.
Crimean-Congo Hemorrhagic Fever Diagnostic Methods
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To guarantee anonymous participation, an individual numerical
identification code was assigned to the results reported by each
laboratory. This number was followed by a letter (a, b, c, d, e)
when distinguishable data sets of results based on different
methods were sent.
The results were scored in reflection of sensitivity and specificity.
Weassigned one pointforcorrect positiveornegativeresultwhereas
false- negatives/-positives results were not scored. Equivocal or
borderline results were not counted. Results for the testing of the
RNA samples were not considered in the scoring system as both
samples seemed to be instable and most of laboratories could not
detect the presence of CCHFV RNA in these samples.
Additionally, results were classified as optimal, acceptable (only
one false-negative result) or need for improvement (false-positive
result and/or several false-negatives).
Statistical analysis
Data collected were entered into Microsoft Excel (Microsoft
Corp., Bellingham, WA, USA). In order to compare the per-
formances of the different diagnostic methods, a chi-square test
and simple logistic regression were performed using STATA/SE
version 12.0 (StataCorp, College Station, USA). As real-time RT-
PCR is the most frequently used method, it has been chosen as the
reference test and its performance has then been compared to the
performance of the other methods: nested RT-PCR, conventional
RT-PCR, real-time combined with nested RT-PCR and real-time
combined with conventional RT-PCR. Test performance was
estimated by calculating the total proportion of correct result for
each method. The p value ,0.01 was considered statistically
significant.
Results
Weobtainedfromtheinviteesaresponserateof94%representing
a total of 44 participating laboratories from 29 different countries (22
European, 3 Asian and 2 American countries, 1 Eurasian and 1
African country):
Medical University of Vienna Department of Virology, Vienna,
Austria; Enzootic and (re)emerging viral diseases, CODA-
CERVA-VAR, Brussels, Belgium; National Reference Vector-
borne infections and Leptospirosis laboratory, National Centre of
Infectious and Parasitic Diseases, Sofia, Bulgaria; Special Patho-
gens Program National Microbiology laboratory, Winnipeg,
Canada; Laboratoire P4 Jean Me ´rieux INSERM, Lyon, France;
IRBA Virology unit, La Tronche, France; Institute of Parasitology
Academy of Sciences of the Czech Republic; Bernhard Nocht
Institut, Hamburg, Germany; Institut fu ¨r Virologie Philipps-
Universita ¨t Marburg, Germany; Diagnostic Division Bundeswehr
Institute of Microbiology, Munich, Germany; Clinical University
of Freiburg, Department of Virology, Freiburg, Germany; TIB
MOLBIOL Syntheselabor GmbH, Berlin, Germany; Robert
Koch Institut, Berlin, Germany; Institute for Novel and Emerging
Infectious Diseases Friedrich-Loeffler-Institut, Greifswald, Ger-
many; Aristotle University of Thessaloniki School of Medicine A9
Department of Microbiology, Greece; National Centre for
Epidemiology virologicke ´ odd., Budapest, Hungary; Arboviruses
and Viral Haemorrhagic Fevers Laboratory (National Ref. Lab)
Pasteur Institute of Iran; Central Virology Laboratory Ministry of
Health, Public Health Laboratories Sheba Medical Centre, Israel;
Laboratory CRREM - U.O. Microbiologia - Policlinico S. Orsola-
Malpighi, Bologna, Italy; Padiglione Baglivi National Institute for
Infectious Diseases ‘‘L. Spallanzani’’, Rome, Italy; Istituto
Zooprofilattico Sperimentale dell’Abruzzo e del Molise ‘‘G.
Caporale’’, Teramo, Italy; Viral Zoonoses Unit Dept. Veterinary
public health & Food safety, Istituto Superiore di Sanita `, Rome,
Italy; Infectiology Centre of Latvia, Riga, Latvia; Centre for
Vectors and Infectious Diseases Research National Institute of
Health, Aguas de Moura, Portugal; Arbovirus and VHF Dia-
gnostic Activity Laboratory of Vector-Borne Infections Cantacu-
zino Institute, Bucharest, Romania; Central Research Institute of
Epidemiology, Moscow, Russia; King Fahd Medical Research
Centre; King Abdulaziz University, Jeddah, Saudi Arabia;
University of Ljubljana, Faculty of Medicine, Institute of Micro-
biology and Immunology, Ljubljana, Slovenia; Arbovirus and
Imported Viral Disease Unit Centro Nacional de Microbiologia
Instituto de Salud Carlos III, Majadahonda, Spain; Area de
Enfermedades Infecciosas, Hospital San Pedro, Logrono, Spain;
Departamento de Microbiologı ´a, Hospital Clinic y Provincial de
Barcelona, Spain; Laboratorio Central de Veterinaria de Algete,
Madrid, Spain; Special Pathogens Unit National Institute for
Communicable Diseases of the National Health Laboratory
Service, Johannesburg, South Africa; Swedish Institute for
Communicable Disease Control, Solna, Sweden; Laboratory of
Virology University of Geneva Hospitals, Geneva, Switzerland;
Virology, Spiez laboratory, Switzerland; Erasmus MC Dept.
Virology, Rotterdam, The Netherlands; Erzurum Hıfzıssıhha
Enstitu ¨su ¨M u ¨du ¨rlu ¨g ˘u ¨, Turkey; Samsun Regional Hygiene Centre,
Turkey; Virology Departement. Refik Saydam National Public
Health Agency, Ankara, Turkey; Firat University, Veterinary
Medicine, Department of Virology, Elazig, Turkey; Special
Pathogens Reference Unit Microbiology Services Health Protec-
tion Agency, Salisbury, United Kingdom; Laboratory of Virology,
Rocky Mountain Laboratories, Hamilton, United States of
America; Viral Special Pathogens Branch, Infectious Diseases,
CDC, Atlanta, United States of America.
Most of these laboratories cannot provide the BSL4 conditions
required to handle infectious CCHFV. Nevertheless they have all
the safety requirements to perform molecular detection of CCHFV
and more specifically this EQA as all testing material provided is
non-infectious.
A total of 53 data sets were received including 3 double sets
from laboratories using 2 methods (sets 13a/b, 34a/b, 35a/b), 1
triple set (2a/b/c) and 1 quintuple data set (42a/b/c/d/e).
A variety of tests were used for detection and identification of
CCHFV genome by participating laboratories. Among the 53
datasets received, we recorded the use of real-time RT- PCR
(n=36, 68%), RT-nested PCR (n=5, 9%), conventional RT-PCR
(n=2, 4%), real-time RT-PCR combined with nested RT-PCR
(n=4, 8%) and real-time RT-PCR combined with conventional
RT-PCR (n=6, 11%) (Table 1 and 2).
Performance varied among laboratories and scores ranged from
2 to the maximum value of 13. Optimal results were reported by
38% (n=20) of the analyses; 19% (n=10) of the analyses achieved
acceptable results due to the inability to detect one positive sample,
and 43% (n=23) revealed several false negative and/or one or
more false positive results showing that there is room for
improvement (Table 1 and 2).
Only 15% of the methods could detect the presence of CCHFV
RNA in the RNA dilutions (samples #3 and #11). These results as
well as previous experiences, indicate us that such RNA pre-
parations are instable and unsuited to EQA studies. For this reason
these samples have not been included in the rest of the evaluation
and scoring system (data not shown).
Statistical analysis shows us that test performance is significantly
associated to the method used, as the p-value is ,0.0001 (Table 3).
The confidence intervals indicate that conventional RT-PCR and
nested RT-PCR are significantly worst-performing than real-time
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Real-time combined with nested RT-PCR and real-time com-
bined with conventional RT-PCR are not significantly performing
differently that real-time RT-PCR only (OR.1 but 1 is not
included in the confidence interval).
Information on the type of protocol used was requested to the
participants and 58% of the data sets included this information.
For the real-time PCR methods, 12 laboratories have reported to
use the protocol from Wo ¨lfel et al., 2007 [30] or 2009 [31]; 3 used
the protocol from Drosten et al., 2002 [32]; 3 used the protocol
from Midilli et al., 2007 [17] and 2009 [33]; 2 used the protocol
from Papa. et al., 2007 [34] and 2 used the protocol from Duh
et al., 2006 [21]. Real-time PCRs were also performed with 3
commercial kits: 4 data sets reported the use of the Real Star
CCHFV RT-PCR kit (1.0 and 1.2) from Altona diagnostics, 2
used the CCHFV real time RT-PCR kit from Shangai ZJ Bio-
Tech Co. and 1 used the LightMix Kit Crimean-Congo Virus of
TIB MOLBIOL. For the nested PCR methods, 2 laboratories
have reported to use the protocol from Rodriguez et al., 1997 [35];
2 used the protocol from Schwarz et al., 1996 [36]; 1 used the
protocol from Deyde et al., 2006 [37]. For the one-step PCR
methods, 1 laboratory has reported to use the protocol from Burt
et al., 1998 [38]; 1 used the protocol from Burt et al., 2005 [39].
The methods employed for each analyze are specified in Table 1
with the reference number.
Laboratories using the same technique differed in their per-
formance, indicating differences in individual operational proce-
dures rather than limitations of the method itself. This is the case
of the 12 laboratories which used the real-time PCR developed by
Wo ¨lfel et al [30], where the corresponding scores ranged from 5 to
13. On the other hand, low performances are observed for
particular methods, thus indicating the need for up-dating or
improving the technique. This can be observed for the one step
PCR from Burt et al [39] and the real-time PCR from Duh et al
[21]. In fact these protocols do not seem to be able to detect the
Afg 09-2990 and ArD 39554 strains. Although this information
should be interpreted with precaution as the number of labo-
ratories reporting the use of these methods is low (n=2).
The sensitivity of the different diagnostic methods might be
assessed by comparing the testing results of the serial dilutions of
CCHFV-Hoti (samples #2, #9, #12, #4, and #14) and CCHFV
Afg09-2990 (samples #10, #5 and #13). Looking at the
percentage of correct results for each sample (Table 1 and 2),
we observe a clear correlation between increased dilution of the
sample and low sensitivity in RNA detection. This decreased
sensitivity is the main reason for reporting false negatives. In fact,
considering test specificity, we observe no major differences in
performance when comparing the testing results obtained for the
different strains and genotypes of CCHFV. However, some results
indicate that specificity issues might be encountered by rarely used
methods such as the protocol from Burt et al [39] and from Duh
et al [21] mentioned in the previous paragraph.
We can also have indications on the specificity of the diagnostic
methods looking at the testing results of the two negative controls
(samples #7 and #8). As much as 13% of the data sets (7 out of
53) reported one or two false positives. All of the corresponding
methods involved real-time PCR but using different protocols.
In order to estimate experience in viral load determination,
further information was requested to the participants on the
number of copies of CCHFV genome detected in the samples.
Over half of the data sets (27 out of 53) reported quantitative
results (data not shown). Among these, 13 reports gave their results
as Ct values proving very limited data to estimate accurately viral
load in the absence of calibrated standards. Interestingly, as much
as 41% of the analyses which mentioned the use of real time-based
procedures (19 out of 46) did not provide information on the viral
load although the use of this method could provide such
quantitative (or at least semi-quantitative) results.
In order to estimate experience in sequencing and strain typing,
strain specification of the CCHFV detected in each sample was
requested to the participants. Only 15% (8 out of 53) of the data
sets reported completely or partially this information (data not
shown). Providing only partial data was mostly due to the inability
to type the Afg 09-2990 and the ArD 39554 strains. In fact out of 8
laboratories performing sequencing, 3 could not type the ArD
39554 strain and 4 could not type the Afg 09-2990 strain in all
dilutions.
The stability of EQA samples was assessed by testing the
samples upon reception in July 2011 and then 3 months later after
storage at room temperature. Excluding the negative results of the
extracted RNA samples, the results indicate that all samples were
stable for a 4 month period (data not shown) and thus demon-
strated that failure in CCHFV RNA detection experienced by
some of the laboratories was probably not due to genome
degradation during shipment or storage.
Discussion
From this study, we can conclude that RNA preparations are
not suitable for such EQA studies. In contrast, the plasmid
preparation seems to be a very useful tool for the evaluation of
diagnostic performance. Furthermore, plasmid preparation does
not require manipulating infectious material which is a great
advantage specially when handling deadly agents such as CCHFV.
From the results of this EQA, it appears clearly that the type of
method used was not the main factor affecting the quality of the
test results. It seems that performance is mostly linked to the
Table 3. Odd ratios obtained for each method by using real-time PCR as the reference.
Method Proportion of correct results OR (95% CI) P-value
No %
Real-time RT-PCR 398/468 85,0% 1.00 (reference) ,0.0001
Conventional RT-PCR 43/65 66,2% 0.34 (0.19–0.61)
Nested RT-PCR 12/26 46,2% 0.15 (0.07–0.34)
Real-time+conventional RT-PCR 46/52 88,5% 1.35 (0.55–3.28)
Real-time+nested RT-PCR 70/78 89,7% 1.54 (0.71–3.34)
OR: odd ratio; CI: confidence interval.
doi:10.1371/journal.pntd.0001706.t003
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their performance differ greatly even when using the same
technique. This result emphasizes the need to revise the protocols
and procedures performed in laboratories with unsatisfactory
results. Moreover, the study cannot designate precisely the best
methods since several factors including primers, enzymes, buffers,
thermocyclers, reaction conditions and genome target all have an
influence on test performance. The influence of this variability is
difficult to estimate but can be minimized by standardizing
protocols including controls and optimizing testing conditions.
However, statistical analysis indicates that real-time RT-PCR is
significantly best-performing than conventional RT-PCR and
nested RT-PCR. Real-time PCR is also the most time effective
method and the only method which enables to quantify directly
the number of genome copies in each sample. However, the major
limitation for the implementation of these assays in endemic areas
is the cost of thermocyclers and reagents which hinder generalized
application in the field. The statistical analysis also enabled us to
conclude that combining real-time RT-PCR with another RT-
PCR method is not showing any significant advantage compared
to the use of real-time RT-PCR only.
CCHF has a low incidence but the disease can be very severe
and cause death. Therefore, the sensitivity of diagnostic tests is of
utmost importance. Reporting false negatives should be considered
more critical than reporting false positives as positive results are
few and can always be submitted to further testing for con-
firmation. Regarding false positive results using real time PCR it is
critical to evaluate properly the obtained curve and the Ct value,
and in doubtful occasions to proceed in gel electrophoresis of the
PCR products, as these false positive results are rather due to non-
specific product rather than to cross contamination.
Most of the participants provided no information regarding
strain typing. However correct results without strain specification
are completely satisfactory in the context of clinical diagnosis as
there is no specific treatment based on each CCHFV strain. On
the other hand, information on the strain type is relevant for
surveillance activities in order to monitor which strain types are
circulating in CCHFV-endemic areas and which type of illness is
associated with these strains.
Information on the quantity of CCHFV RNA in human plasma
samples can be very useful for pathogenesis studies and for
monitoring the progress of clinical manifestations. In fact, it has
been shown in several studies that viral load is a useful predictor of
disease progress, with high viral load tending to indicate fatal
outcome [30,34,40,41]. In our study, most data sets (87%) re-
ported the use of real-time PCR which enables at least semi
quantitative RNA quantification. However, less than 60% of these
results provided this information as RNA concentrations or as cut-
off values, indicating there is still room for improvement con-
cerning viral load determination as mentioned in previous EQA
studies [23].
The increasing importance of this disease in Africa, Asia and the
Middle-East, and the risk of expansion to other areas such as
Europe makes necessary to assure that the methods used for the
diagnosis and surveillance of CCHFV are working properly where
they are already implemented. Indeed the low participation from
endemic countries in this EQA, even if thoroughly announced,
is pointing out the need to encourage more laboratories to
implement CCHFV diagnosis techniques suited to their capacity
and capability and to participate routinely in quality assurance
programs.
In order to reach optimal performances for CCHFV molecular
diagnosis in reference laboratories, we recommend performing
such EQA studies on a regular basis. Future EQA studies should
include a range of CCHFV genotypes and concentrations to
reflect more accurately diagnostic performances in expert labora-
tories. Additionally, the EQA instructions should clearly mention
to participants that complete information on the methods used is
required in order to obtain better results and accurate conclusions.
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